Treatment of central nervous system leukemia with CD19-chimeric antigen receptor T-cell immunotherapy: two cases report and literature review.
10.3760/cma.j.issn.0253-2727.2018.08.008
- Author:
Meng Ying JIN
1
;
Yue HAN
;
Yue Jun LIU
;
Bin GU
;
Jia CHEN
;
Sen Sen SHI
;
Ming Zhu XU
;
Cheng Sen CAI
;
Ya Qiong TANG
;
De Pei WU
Author Information
1. The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Collaborative Innovation Centre of Hematology, Institute of Hematopoietic Stem Cell Transplantation, Key Laboratory of Thrombosis and Haemostasis of Ministry of Health, Suzhou 215006, China.
- Publication Type:Review
- Keywords:
Central nervous system leukemia;
Chimeric antigen receptor T-cell immunotherapy;
Leukemia
- MeSH:
Antigens, CD19;
Humans;
Immunotherapy, Adoptive;
Receptors, Antigen, T-Cell;
Receptors, Chimeric Antigen;
T-Lymphocytes
- From:
Chinese Journal of Hematology
2018;39(8):650-653
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the efficacy and safety of chimeric antigen receptor T (CAR-T) cells in the treatment of central nervous system leukemia (CNSL). Methods: Two leukemia patients with CNSL were treated with CD19-CAR-T cells. The process and results of the entire treatment is reported and related literature review is conducted. Results: The patients were diagnosed as acute myeloid leukemia (AML)-M(2) with B lymphoid antigen expression and B cell acute lymphoblastic leukemia(B-ALL) by morphology and immunophenotype assay. The immunophenotype was consistent with the abnormal manifestations of AML-M(2) and B-ALL. Their clinical manifestations and laboratory tests met the diagnostic criteria of CNSL. The diagnosis was clear and the two patients were treated with CD19-CAR-T cell immunotherapy. Central nervous system symptoms were relieved. The imaging abnormalities of patient one has disappeared but cytokines release syndrome (CRS) occurred during the treatment. Cerebrospinal fluid of patient two was negative and no obvious CRS reaction was found. Conclusions: CAR-T cell immunotherapy is likely to induce the remission of CNSL and improve the prognosis.